FOXM1 and PD-L1 in CDK4/6-MEK resistance in nerve tumors
“We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent exciting future treatment options for MPNST patients.”
BUFFALO, NY- October 1, 2024 – A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors.”
As highlighted in the abstract of this paper, malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, Ras-driven sarcomas characterized ...


















